AVA6207 Overcomes TOP1i Resistance

Summary by AI BETAClose X

Avacta reported preclinical data showing AVA6207, a dual exatecan+berzosertib pre|CISION® PDC, reversed TOP1i resistance in vitro and in vivo, producing complete responses in 100% (ovarian) and 80% (4/5 NSCLC) of animals, demonstrating approximately 10-fold higher sensitivity in ATM-deficient cells, showing superiority to marketed ADC Enhertu in a gastric PDX, and with payloads selected the clinical candidate moves to IND-enabling studies in Q4 2026, supporting a biomarker-enriched clinical strategy targeting addressable populations such as ~150,000–250,000 annual NSCLC cases and 4,000–20,000 ESCC cases.

Disclaimer*

UK 100

Latest directors dealings